Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

Phylogica Limited (ASX:PYC), which has zero-debt on its balance sheet, can maximize capital returns by increasing debt due to its lower cost of capital. However, the trade-off is PYC will have to ...

The S&P/ASX 200 Index (ASX: XJO) is struggling on Wednesday and on course to record a disappointing decline. In afternoon trade, the benchmark index is down 0.8% to 8,809.2 points. Four ASX shares ...

The considerable ownership by individual investors in PYC Therapeutics indicates that they collectively have a greater say in management and business strategy A total of 9 investors have a majority ...

PYC Therapeutics Limited (AU:PYC) has released an update. PYC Therapeutics Limited has announced a significant breakthrough in treating Phelan-McDermid Syndrome (PMS), a rare neurodevelopmental ...

PYC Therapeutics Limited (AU:PYC) has released an update. PYC Therapeutics, a clinical-stage biotech firm focused on RNA therapies, is poised to release groundbreaking efficacy data for its novel ...

PYC Therapeutics (ASX: PYC) presented its Q2 2025 investor webinar on May 30, outlining progress across its genetic medicine pipeline while facing continued market skepticism. The company’s stock ...

PYC Therapeutics raised AU$40 million of an anticipated AU$74 million (US$48.6 million) capital raise to advance three candidates, including lead candidate VP-001, which could potentially be the first ...

PYC Therapeutics Limited ( (AU:PYC)) has shared an announcement. PYC Therapeutics has issued 2,000,000 unlisted options to director Peter Coleman under an exception to ASX Listing Rule 10.12, with ...